Evaluaton of prophylactic effect of alpha lipoic acid on oral mucositis

Evaluaton of prophylactic effect of alpha lipoic acid on oral mucositis in patients undergoing head and neck radiotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220607055099N1

Enrollment

Registered

2023-07-19

Start date

2023-07-21

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral mucositis. Oral mucositis

Interventions

Intervention group: alpha lipoic acid capsules 300 mg twice a day, 2 capsules each time during radiotherapy sessions to be consumed by the patients for two weeks afterwards. Alphalipoic acid (Raha Pha

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with oral and nasopharyngeal cancer treated with a total radiation dose of 5600-7000 cGy

Exclusion criteria

Exclusion criteria: Pregnant patients Patients under 18 years old Patients with diabetes, thyroid disease, and liver disease Alcohol users

Design outcomes

Primary

Measure	Time frame
Degree of mucositis. Timepoint: Weekly from the first day of radiotherapy to 2 weeks after radiotherapy. Method of measurement: According to the clinical criteria of the World Health Organization.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam jarahzade

Shahid Beheshti University of Medical Sciences

maryam.jarahzade92@gmail.com+98 21 2217 5350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026